Publications

Icosavax-licensed VLP technology

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity Arunachalam PS, et al. Nature (2021), 253–258.
Quadrivalent influenza nanoparticle vaccines induce broad protection Boyoglu-Barnum, et al. Nature (2021), 623–628.
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 Walls AC, et al. Cell (2020), 1367–1382.
Self-assembling nanoparticles usher in a new era of vaccine design Rappuoli R and Serruto D. Cell (2019), 1245–1247.
Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus Marcandalli J, et al. Cell (2019), 1420–1431.

Background third-party publications on diseases and antigens relevant to Icosavax vaccine candidates

Evaluation of Viruses Associated With Acute Respiratory Infections in Long-Term Care Facilities Using a Novel Method: Wisconsin, 2016‒2019 Checovich MM, et al. JAMDA (2020), 29 – 33.
Comparative incidence and burden of respiratory viruses associated with hospitalization in adults in New York City Sieling WD, et al. Influenza Other Respi Viruses (2021), 670 – 677
Another Piece of the Puzzle: Human Metapneumovirus Infections in Adults Walsh EE, et al. Arch Intern Med (2008), 2489 – 2496
Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins Hsieh CL, et al. Nature Communications (2022).
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial Ruckwardt TJ, et al. The Lancet Respiratory Medicine (2021).
A proof of concept for structure-based vaccine design targeting RSV in humans. Crank MC, et al. Science (2019), 505–509.
Epidemiology of viral pneumonia Jain S. Clinics in Chest Medicine (2017), 1–9.
Rates of hospitalization for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults Widmer K, et al. Journal of Infectious Diseases (2012), 56–62.
Humoral immunity to human metapneumovirus infection in adults Falsey A, et al. Vaccine (2010), 1477–1480.
Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines–nonadjuvanted vaccine or vaccine adjuvanted with alum–given concomitantly with influenza vaccine to high-risk elderly individuals Falsey A, et al. Journal of Infectious Diseases (2008), 1317–1326.

Background third-party publications demonstrating potential magnitude, duration, and breadth of response with VLP vaccines

Explanations for the high potency of HPV prophylactic vaccines Schiller J and Lowy D. Vaccine (2018), 4768–4773.
Cross-protective efficacy of HPV-16/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Wheeler CM, et al. Lancet Oncology (2012), 100–110.